BARDA Archives - Page 2 of 2 - EverGlade Consulting

BARDA

BioMaP-RPP-N95-respirators

BARDA Issues RPP for N95 Respirator Production

Leave a Comment / All Posts, BARDA, Life Sciences / By

BioMaP_RPP_24-05-N95 The Biomedical Advanced Research and Development Authority (BARDA) has released an essential Request for Project Proposals (RPP) aimed at sustaining the manufacturing capacity of N95 respirators, a crucial element in the biopharmaceutical and healthcare sectors, especially highlighted during the COVID-19 pandemic. The RPP, numbered 24-05-N95, focuses on maintaining a “warm-base” status of manufacturing capabilities […]

BARDA Issues RPP for N95 Respirator Production Read More »

Single-dose Vaccine

BARDA Issues RFI for Developing Single-Dose Pandemic Influenza Vaccine

Leave a Comment / All Posts, BARDA, Life Sciences / By

The Biomedical Advanced Research and Development Authority (BARDA), part of the Administration
for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human
Services (HHS), is seeking innovative ideas and strategies to develop a single-dose vaccine for pandemic
influenza. This Request for Information (RFI) is designed to gather valuable insights from
biopharmaceutical companies, research institutions, and vaccine development experts to facilitate the
creation of a vaccine that offers durable immunity with a single administration.

BARDA Issues RFI for Developing Single-Dose Pandemic Influenza Vaccine Read More »

Filovirus Monoclonal Antibodies

BARDA Announces RPP for Manufacturing Optimization for Filovirus Monoclonal Antibodies

Leave a Comment / All Posts, BARDA, Life Sciences / By

The Biomedical Advanced Research and Development Authority (BARDA) has issued a Request for Project Proposals (RPP) for “Manufacturing Optimization for Filovirus Monoclonal Antibodies.” The RPP was released on June 24, 2024, with proposals due by July 22, 2024. This initiative aims to enhance the manufacturing development of monoclonal antibody (mAb) cocktails targeting filoviruses like Ebola and Marburg viruses.

BARDA Announces RPP for Manufacturing Optimization for Filovirus Monoclonal Antibodies Read More »

Abstract virus on blue background

BARDA Announces Request for Project Proposal to Establish Central Influenza and Emerging Infectious Diseases Vaccine Immunogenicity Laboratory Services

Leave a Comment / All Posts, BARDA, Life Sciences / By

Biomedical Advanced Research and Development Authority (BARDA) through the Rapid Response Partnership Vehicle (RRPV) initiative released a Request for Project Proposals (RPP) to establish Central Influenza and Emerging Infectious Diseases Vaccine Immunogenicity Laboratory Services to support vaccine development and response to pandemics and emerging infectious diseases.

BARDA Announces Request for Project Proposal to Establish Central Influenza and Emerging Infectious Diseases Vaccine Immunogenicity Laboratory Services Read More »

Medical Countermeasures through BARDA

BARDA Announces Request for Project Proposal for On-Demand Manufacturing

Leave a Comment / All Posts, BARDA, Life Sciences / By

The Biomedical Advanced Research and Development Authority (BARDA) is spearheading this effort with its innovative On-Demand Manufacturing program. This initiative is designed to revolutionize the production and distribution of MCMs by developing portable, continuous, and end-to-end manufacturing systems.

BARDA Announces Request for Project Proposal for On-Demand Manufacturing Read More »

BARDA Issues Amendment 4 to BAA for Medical Countermeasures R&D

BARDA Issues Amendment 4 to BAA for Medical Countermeasures R&D 

Leave a Comment / All Posts, BARDA, Life Sciences / By

BARDA has recently unveiled significant updates to its BAA, emphasizing a more refined and responsive approach to public health preparedness. Amendment 4 introduces crucial changes to the Areas of Interest designed to align BARDA’s efforts with the evolving landscape of global health threats.

BARDA Issues Amendment 4 to BAA for Medical Countermeasures R&D  Read More »

BARDA Issues Amendment 3 to BAA for Medical Countermeasures R&D

BARDA Issues Amendment 3 to BAA for Medical Countermeasures R&D 

Leave a Comment / All Posts, BARDA, Life Sciences / By

The Biomedical Advanced Research and Development Authority (BARDA) has recently unveiled significant updates to its Broad Agency Announcement (BAA), emphasizing a more refined and responsive approach to public health preparedness. Amendment 3, in particular, brings crucial changes to the Areas of Interest (AOIs) that are designed to align BARDA’s efforts with the evolving landscape of global health threats. 

BARDA Issues Amendment 3 to BAA for Medical Countermeasures R&D  Read More »

Covid Research

EverGlade Consulting Lands ModeX Therapeutics Up to $168 Million in BARDA Funding

Leave a Comment / All Posts, BARDA, Life Sciences / By

EverGlade Consulting, a national consulting firm, has helped ModeX Therapeutics successfully secure up to $168 million in funding through a contract with the Biomedical Advanced Research and Development Authority (“BARDA”) to develop novel multispecific antibodies against viral infectious disease threats. How Funding Will Be Used The $168 million in BARDA funding will advance research and clinical trials for multispecific

EverGlade Consulting Lands ModeX Therapeutics Up to $168 Million in BARDA Funding Read More »

BARDA Post-Award represented with a digital drawing of virus and microscope

Effective Post-Award Management of a BARDA Contract

Leave a Comment / All Posts, BARDA, Guides, Life Sciences / By

The Biomedical Advanced Research and Development Authority (BARDA) plays a pivotal role in the United States’ preparedness for public health emergencies. BARDA contracts support the development, procurement, and deployment of medical countermeasures critical for safeguarding public health during crises. Once awarded a BARDA contract, effective post-award management becomes paramount to ensure the successful execution of

Effective Post-Award Management of a BARDA Contract Read More »

medical countermeasures development

Guide to BARDA Funding Broad Agency Announcement Update

Leave a Comment / All Posts, BARDA, Guides, Life Sciences / By

The Biomedical Advanced Research and Development Authority (BARDA), a USG agency that operates within the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), has recently released a new, modernized Broad Agency Announcement (BAA) with the goal of enhancing efficiency, improving responsiveness, and reducing

Guide to BARDA Funding Broad Agency Announcement Update Read More »

Antibodies attacking virus cell for BARDA Funding Guide

A Guide to BARDA Funding

Leave a Comment / All Posts, BARDA, Guides, Life Sciences / By

A Guide to BARDA Funding: Application Process, Financial and Technical Requirements A Comprehensive Guide to BARDA Funding The Biomedical Advanced Research and Development Authority, commonly known as BARDA, has played a pivotal role in safeguarding public health in the United States and beyond. Since its inception, BARDA has bolstered the country’s preparedness and response capabilities

A Guide to BARDA Funding Read More »

Scroll to Top